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ABSTRACT 
Background: Steroid-resistant ephrotic syndrome (SRNS) with focal segmental glomerulosclerosis has 
emerged as a leading cause of end-stage renal failure (ESRF) in children and adults. In the past decade, immuno- 
suppressive drugs such as cyclosporine (CsA) and cyclophosphamide have been introduced for the treatment of 
SRNS, but data on long-term clinical outcome (over years) are lacking. 
Objective: The current study considered the clinical outcome of patients with SRNS who had been treated 
with CsA for >2 years. The primary objective was to evaluate renal function after years of treatment compared 
with nontreated or CsA-resistant patients. A secondary objective was to identify renal effects related to the use 
of CsA, with a major emphasis on renal fibrosis. 
Methods: In this open-label, nonrandomized, retrospective study, the outcomes of patients of all ages with 
sporadic SRNS who had been followed up for >2 years (between 1970 and 2002) at 4 Italian clinical institutions 
were evaluated. Preliminary molecular screenings for genes encoding proteins of the slit-diaphragm (eg, podocin, 
nephrin, ~z-actinin) were performed to exclude inherited forms of sporadic SRNS. 
Results: A total of 157 patients were studied; mutations were found in 18 patients (11%). Of the remaining 
139 patients (84 men, 55 women; median [interquartile range (IQR)] age at onset of proteinuria, 12 [4-32] 
years), 84 (60%) were nontreated and 55 (40%) were treated with CsA. Of these 55 treated patients, 35 (64%) 
were found to be resistant (ie, persistence of proteinuria fter 2 months) or intolerant (ie, malignant hyperten- 
sion or worsening of renal function), and CsA was withdrawn. The median (IQR) durations of follow-up for CsA- 
resistant and nontreated patients were 41 (23-92) and 48 (28-106) months, respectively. Twenty patients (36%) 
were responsive to CsA and were followed up for a median (IQR) of 81 (47-115) months. Progression to ESRF 
occurred in 10% of CsA-responsive patients versus 60% of CsA-resistant patients and 62% of nontreated patients 
(P = 0.002). No sign of renal fibrosis related to drug toxicity was observed in renal biopsies performed at 5-year 
intervals. 
Conclusions: This retrospective analysis of SRNS documented a persistent antiproteinuric effect of long-term CsA 
(>2 years) in the absence of renal fibrosis. Although sensitivity to CsA was associated with normal renal function, 
resistance or intolerance was associated with progression to ESRE These data suggest that CsA may have a role in 
the treatment of patients with SRNS. (Clin Ther. 2004;26:1411-1418) Copyright @ 2004 Excerpta Medica, Inc. 
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INTRODUCTION 
Steroid-resistant nephrotic syndrome (SRNS) associ- 
ated with focal segmental glomerulosclerosis (FSGS) 
is one of the most frequent glomerular diseases in 
children and adults 1 and has emerged as a leading 
cause of end-stage r nal failure (ESRF).l The estimated 
incidence in US children (age, <14 years) is 2.0 to 2.7 
per 100,000 per year, with a cumulative prevalence of
16 per 100,000. 2 Geographic or ethnic differences 
have been reported, with a 6-fold greater incidence in 
Asian than in European children. 2,3 SRNS appears to 
be a clinical heterogeneous condition characterized 
by histologic variants, *-6 different genetic back- 
grounds, r-9 and variable responses to drugs. ~o,~ The 
pathologic picture in these patients is mainly repre- 
sented by focal area of segmental glomerulosclerosis 
that often coexists with diffuse mesangial immuno- 
globulin (Ig) M deposition, 12,13 and the boundary 
between the 2 entities cannot always be defined. ~,,~5 
The typical clinical hallmark of these patients is strict 
resistance to steroids that are invariably used as a 
first-line therapy. 
Cyclosporine (CsA) was introduced in 1993 as a 
therapeutic option for treating patients with SRNS ~6 
because it had been proved effective in the short-term 
(ie, within 1 year) management of proteinuria, lr m 
and randomized studies it-19 confirm this effect. 
Unfortunately, the long-term administration of CsA 
(over years) carries the potential for renal toxicity, 2° 
and historical trials considered only short-term regi- 
mens lasting <1 year. Now, long-term (>4 years) reg- 
imens with low-dose (2-3 mg/kg body weight) CsA 
are widely applied in clinical practice, thus allowing 
satisfactory control of proteinuria nd potentially low 
toxicity. Studies on the effectiveness and safety of CsA 
in SRNS are needed to consolidate the wide clinical 
popularity of the drug. Despite clear limitations, 
retrospective, nonrandomized studies should repre- 
sent a first-line approach to defining the clinical out- 
come in patients with SRNS treated for >2 years with 
CsA. A central issue in such studies is to exclude 
carriers of inherited SRNS due to mutations of one 
of the proteins of the slit-diaphragm because they 
mimic noninherited types while presenting invariable 
and rapid progression to ESRE In particular, muta- 
tions of podocin, one of the major genes causing a 
recessive type of FSGS, have been described in a sig- 
nificant proportion (-10%) of patients with sporadic 
SRNS who inherited the defects as an autosomal 
recessive trait21-23; these patients hould be identified 
and excluded in studies looking at the pharmacologic 
approach to SRNS. 
In the current study, we considered the clinical out- 
come of patients with SRNS who had been treated with 
CsA for >2 years. The primary objective was to evaluate 
renal function after years of treatment compared with 
that of nontreated or CsA-resistant patients. A second- 
ary objective was to identify any renal effects related to 
the use of CsA, with a major emphasis on renal fibrosis 
(a major renal adverse ffect of the drug). 2° 
PATIENTS AND METHODS 
We retrospectively studied patients of all ages 
with sporadic SRNS who had been followed up for 
>2 years (between 1970 and 2002) at 4 Italian clinical 
institutions and for whom DNA was collected for 
molecular analysis. Inclusion criteria were the presence 
of nephrotic proteinuria (urinary protein excretion, 
>40 mg/kg-d) and the availability of a renal biopsy with 
proven FSGS lesions (___1 segmental sclerotic area) with 
or without IgM deposition. In all cases, the therapeutic 
approach was to start with steroids adhering to wide- 
ly used regimens l°,n (60 mg/m2-d for 30-60 days) and, 
in cases of nonresponsiveness (partial or global), 
steroids were combined or substituted with cyclophos- 
phamide (2 mg/kg-d for 60 days) and/or with CsA 
(5 mg/kg-d starting dose, followed by tapering to reach 
the minimum dose required for maintaining CsA serum 
trough levels between 50 and 100 ng/mL). In cases of 
persistent steroid/CsA resistance, methylprednisolone 
was given in pulses (10 mg/kg; 6 cycles). Steroid 
resistance was considered to be the failure to achieve 
remission of proteinuria (urinary protein excretion, 
<2 mg/kg-d) after 4 weeks of steroid treatment. CsA 
resistance was the failure to modify proteinuria fter 
8 weeks of CsA at a starting dose of 5 mg/kg. CsA 
intolerance was the worsening of renal function (creat- 
inine clearance <70% of pre-CsA values) and/or the 
increment of mean arterial blood pressure (___50%) 
after the start of therapy. 
General clinical parameters studied included blood 
cell counts; levels of serum creatinine, urea cholesterol, 
and triglycerides; and liver function tests performed 
according to international standardized procedures. 
Renal biopsies were processed using standard pro- 
cedures that included hematoxylin-eosin, periodic 
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acid-Schiff, and green Masson stainings of formalin- 
included pieces; immunofluorescence of frozen sam- 
ples was carried out with a panel of antiserum protein 
antibodies against IgA, IgM, IgG, C3, and C4. Biopsy 
samples were evaluated by a pathologist, who dis- 
cussed all pertinent aspects with the referring clini- 
cians. The relevant clinical and pathologic features (ie, 
sex, age at onset of proteinuria, nd progression toward 
ESRF) are reported. The basic molecular approach 
included sequencing of podocin, nephrin, and c¢- 
actinin 4, which are proteins of the glomerular slit- 
diaphragm whose mutations are invariably associated 
with SRNS and rapid progression to ESRF. Adult 
patients or parents of patients aged < 18 years provided 
written informed consent for DNA analysis and for the 
statistical review of the clinical variables. Consensual 
patients were numbered, and data were evaluated on 
an anonymous basis, access key numbers being in pos- 
session of the senior author (G.M.G.). We also had per- 
mission to collect blood and analyze clinical data from 
patients with SRNS starting from 1995 by the chief of 
the Department ofNephrology at G. Gaslini Children~ 
Hospital; this permission was renewed in 2001. At the 
time this study was initiated, this approval was 
required for retrospective studies. 
Mutat ion Analysis 
We obtained peripheral blood samples for genetic 
analysis from the enrolled patients and from selected 
parents and siblings. Five milliliters of blood in ethyl- 
enediaminetetraacetic acid (EDTA) was obtained on the 
morning after an overnight fast, rapidly frozen in plas- 
tic vials, and maintained at -20°C. Genomic DNA was 
extracted according to standard procedures. Molecular 
analyses of podocin and nephrin were performed by 
direct sequencing as described previously r,9,21 Primer 
sequences for podocin were selected on the basis of lit- 
erature reports by different groups] In particular, for 
exons 2 and 6 primer design, we followed the guide- 
lines of Ruf et a123 to avoid the presence of a recognized 
single nucleotide polymorphism. Exons were amplified 
by polymerase chain reaction using flanking intronic 
primers and subjected to automatic sequence analysis 
by dye-terminator reaction (ABI 3100 Automated 
Sequencer, Applera Corporation, Milan, Italy). For c¢- 
actinin 4, the "hot-spot" A682G and C695T mutations 
at exon 8 were detected by restriction site analyses as 
described by Kaplan et al. 8 
Statistical Analysis 
Data are expressed as median (interquartile range 
[IQR]). Because all quantitative variables did not pre- 
sent a normal distribution, box plots and nonparametric 
tests were used to represent and compare the distribu- 
tions of age at onset of proteinuria in groups defined by 
the response to pharmacologic treatments. In box plots, 
horizontal lines display the 10th, 25th, 50th, 75th, and 
90th percentiles of a variable. 
The influence of any general (eg, sex, age at onset 
of proteinuria) and clinical (eg, histology, pharmaco- 
logic treatments) variables on the progression to 
ESRF was investigated using the multivariate Cox 
regression model (proportional hazards). 
Kruskal-Wallis analysis was employed to compare 
the median age of patients responsive to CsA with 
that of those who were resistant or nontreated. 
Kaplan-Meier plots and log-rank tests were used to 
assess whether survival differed significantly among 
subgroups defined according to sex or pharmacolog- 
ic treatment. P values <0.05 were considered signifi- 
cant. StatView version 5.0.1 (SAS Institute Inc., Cary, 
North Carolina) was used in the statistical approach. 
In this analysis, the event ime variable measures the 
time elapsed between onset of proteinuria nd the 
beginning of dialysis. Because the observational peri- 
od ended in December 2002, those patients who did 
not reach the event at that time were censored. 
RESULTS 
The cohort of 157 patients described here was part 
of a large series of patients with SRNS and FSGS 
who had been followed up between 1970 and 2002 
at 4 Italian institutions and for whom clinical data 
of the follow-up were available. This series does not 
include all patients with SRNS followed up at these 
institutions, but only those for whom a DNA sam- 
ple was collected, allowing for a molecular classifi- 
cation. Mutation screenings for components of 
the slit-diaphragm were, in fact, considered essential 
to exclude those patients who presented with 
an inherited type of FSGS, still having sporadic 
disease. Mutations of podocin were found in 17 
patients (11%); nephrin was mutated in 1 (<1%). 
According to our protocol, carriers of podocin and 
nephrin mutations were excluded from the present 
study and are described in detail elsewhere21,2~; 
they represent a separate cohort of patients with 
1413 
CLINICAL THERAPEUTICS ® 
invariable progression to ESRF despite any pharma- 
cologic treatment. 
Of the remaining 139 patients (84 men, 55 
women; median [IQR] age at onset of proteinuria, 
12 [4-32] years), 45 (32%) were treated with 
cyclophosphamide without any clinically relevant 
effect (Table). Eighty-four patients (60%) received 
no treatment, and 55 (40%) were treated with CsA. 
Of these 55 patients, 35 (64%) were found to be 
resistant or intolerant o the drug; the drug was 
then withdrawn in these patients. In 20 patients 
(36%), CsA induced a complete remission of pro- 
teinuria, which is stable normalization of urinary 
protein levels over time (median [IQR] follow-up, 
81 [47-115] months). The median (IQR) follow-up 
for patients sensitive to CsA was 81 (47-115) 
months (50% of cases had been followed up for 
4-10 years). Patients who were CsA resistant or 
were nontreated had shorter median (IQR) follow- 
ups of 41 (23-92) and 48 (28-106) months, re- 
spectively, as most of these patients progressed to 
ESRF during the follow-up period. No cases of liver 
damage and/or gastrointestinal disturbances (eg, 
nausea, vomiting, abdominal pain, anemia, hyper- 
kalemia) were observed. 
As shown in Figure 1, CsA was used mostly in 
young patients with steroid resistance. In fact, most 
patients who had been treated with CsA were chil- 
dren (median age, 5 and 8 years for responders and 
resistant patients, respectively; IQR for responders 
and resistant patients combined, 8-10); the median 
(IQR) age of nontreated patients was 19 years 
(8-44 [H = 17.998; P < 0.001). CsA sensitivity was 
associated with long-term (over years) preservation of
renal function. No single general or clinical parameter 
was predictive of the antiproteinuric response of CsA. 
In the panel of clinical factors associated with CsA 
response and outcome of renal function, we did not 
consider prevalence of hypertension and treatment 
because the pharmacologic approach to hypertension 
varied over years, and clear information was not avail- 
able. Figure 2 shows the cumulative survival (consid- 
ering ESRF that required a substitutive treatment as 
the end point) of responders and CsA-resistant 
patients. Two of 20 responders (10%) had progres- 
sion to ESRF compared with 21 of 35 (60%) in the 
Table. Baseline demographic and clinical characteristics of patients with steroid-resistant nephrotic syndrome followed up 
for >2 years at 4 Italian institutions between 1970 and 2002.*t 
CsA Responsive CsA Intolerant or Resistant No CsATreatment All Patients 
Characteristic (n = 20) (n = 35) (n = 84) (N = 139) 
Demographic 
Sex, no. (%) 
Hale 14 (70) 22 (63) 48 (57) 84 (60) 
Female 6 (30) 13 (37) 36 (43) 55 (40) 
Clinical 
Age at proteinuria onset, median (IQR), y 5 (3 I I) 8 (4 14) 19 (8~i4) 12 (4 32) 
Histology, no. (%) 
FSGS 17 (85) 28 (80) 78 (93) 123 (88) 
Hes.-IgH 3 (I 5) 7 (20) 6 (7) 16 (I 2) 
Cyclophosphamide response, no. (%) 
Responsive 0 (0) I (3) 5 (6) 6 (4) 
Unresponsive 9 (45) 14 (40) 16 (I 9) 39 (28) 
Not determined II (55) 20 (57) 63 (75) 94 (68) 
ESRF, no. (%) 2 (I 0) 21 (60) 52 (62) 75 (54) 
Follow-up, median (IQR), mo 81 (4~115) 41 (2342) 48 (28 106) 48 (28 105) 
CsA = cyclosporine; IQR = interquartile range; FSGS = focal segmental glomerulosclerosis; MesAgM = mesangial proliferative glomerulonephritis with 
immunoglobulin M deposition; ESRF = end-~age renal failure. 
*No significant between-group differences were found. 
tThis cohorL was parL of a large series of nephrotic patients for whom a DNA sample was available and was utilized for screening of podocin and nephrin 
mutations. Those patients carrying a mutation were excluded from the study and described elsewhere. 21,24 
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Figure I. Median age at onset of proteinuria in patients with steroid-resistant nephrotic syndrome. Because all quantitat ive 
variables did not present a normal distribution, box plots and nonparametric tests were used to represent and 
compare the distributions of age at onset of proteinuria in groups defined by the response to pharmacologic 
t reatments .  In box plots, horizontal lines display the 10th, 25th, 50th, 75th, and 90th percentiles of a variable. 
Patients who were treated with cyclosporine (CsA) were younger than those who were not treated (H = 17.998; 
P < 0.001 [KruskaI-Wallis]). 
resistant group and 52 of 84 nontreated patients 
(62%) (P = 0.002). Thirteen patients (60%) in the 
group with CsA sensitivity presented with _> 1 pro- 
teinuria relapse after a follow-up of >3 years and were 
treated with steroids. In a few cases, low-dose steroids 
(0.1-0.5 mg/kg-d) were necessary to maintain 
proteinuria within the normal range, suggesting that 
a type of steroid dependence may occur in some 
patients, in which case CsA was able to determine a
change in sensitivity to steroids from strict resistance 
to dependence. Patients treated with CsA for >4 years 
had a renal biopsy at 5-year intervals, and in no in- 
stance did we observe relevant tubulointerstitial fi-
brosis. Accordingly, the drug was not withdrawn in 
any patient. 
DlSgt lSS lON 
SRNS associated with FSGS is an emerging cause of 
ESRF in children and adults. 1,25 Because FSGS, and 
SRNS in general, is not a homogeneous disease but 
has different clinical and genetic backgrounds, factors 
associated with progression must be identified. The 
first issue is the genetic background relative to pro- 
teins of the slit-diaphragm, r-9 Some reports 21,23,2~,26 
published between 2001 and 2004 demonstrated 
that a significant proportion of children with SRNS 
and FSGS have homozygous mutations of podocin. 
In most of these patients, whose disease was not dis- 
tinguishable on clinical grounds from idiopathic 
FSGS, the disease progressed to ESRF within the sec- 
ond decade of life, indicating the key involvement 
genetic background has in progression. A second 
potential factor associated with progression to ESRF 
in patients with FSGS is responsiveness to therapies; 
steroid sensitivity has been indicated previously as 
the most useful criterion to identify patients whose 
disease progresses. 2r,28 A basic issue is how to define 
steroid resistance because new reports suggest an IV 
route of methylprednisolone pulses, > and data from 
the literature clearly show that it is in patients who 
are resistant to steroids that progression is com- 
mon. 3°,31 In steroid-resistant patients, CsA represents 
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the second line of defense. This drug was introduced 
in 1993 as a therapeutic option for treating SRNS, but 
its use was restricted to short periods. 16 One major 
reason for brief courses of treatment with CsA is the 
strong profibrotic effect of the drug that has been 
documented. 2° Currently, CsA is used at a low dose 
(2-3 mg/kg body weight) for >5 years. 16,3o Few long- 
term studies considering the adverse effects of this 
low dose are available. A literature search of PubMed 
for articles on CsA therapy for SRNS published 
between 1987 and 2004 (key words: nephrotic zyn- 
drome and cyclosporine with restriction to focal segmen- 
tal glomerulosclerosis) identified 47 articles, most 
referring to drug treatment of 1 year. Our study 
cohort consisting of patients with sensitivity to CsA 
had a median 81-month follow-up and represents he 
group with idiopathic SRNS with the longest period 
so far reported. 
With the clear limitations of a retrospective r view of 
nonrandomized patients, the results of our study 
report data on a cohort of patients with FSGS charac- 
terized for molecular aspects of the slit-diaphragm pro- 
teins who had been treated for significant periods of 
time. Patients with steroid and CsA resistance repre- 
sent the bulk of our study cohort, and data here con- 
firm that progression to ESRF is frequent in these cases 
and involved -50% of patients. According to the 
cumulative survival rate reported in Figure 2, sensitiv- 
ity to CsA appears to be the major factor influencing 
long-term outcome in patients with SRNS. This behav- 
ior was mainly influenced by those patients who had 
remission of proteinuria during pharmacologic treat- 
ment, evidenced by the fact that only 2 of the cohort of 
20 patients in whom CsA elicited an antiproteinuric 
effect had progression to ESRF. What mediates progres- 
sion to ESRF in patients intolerant o CsA is currently 
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Figure 2. Cumulative survival in patients with steroid-resistant nephrotic syndrome who were treated (n = 55) or not treated 
(n = 84) with cyclosporine (CsA).The treatment group was subdivided into patients who had an antiproteinuric 
response to CsA (n = 20) and patients who were intolerant or had no response at all (n = 35). The end point was 
end-stage renal failure that required a substitutive treatment. Events are indicated at the bottom. Censored patients 
are indicated as a vertical tract in each cumulative curve. Log-rank test, chi-square test, 12.448; df  = 2; P = 0.002. 
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unknown. It is reasonable to hypothesize that intrac- 
table proteinuria triggers a series of events leading to 
tubulointerstitial fibrosis. However, evaluation of these 
patients was not within the scope of the current study, 
and studies on genetic predisposition for developing 
fibrosis are in progress. The observation that CsA may 
reduce proteinuria in some patients who were resistant 
to steroids is not new and confirms previous data by 
Cattran et a119 and Niaudet) 1Our report incorporates 
the observation that CsA not only improves protein- 
uria but also ameliorates the long-term outcome and 
reduces the incidence of ESRF in patients with SRNS. 
Data from the current study demonstrate hat CsA at a 
low dose may be used for several years without clini- 
cally relevant adverse ffects. 
Unfortunately, the present study indicates that CsA 
is used mainly in children, which leads to the ques- 
tion of why most adults with SRNS are not treated 
with this drug (median age of nontreated patients, 18 
years). Overall, data on long-term CsA treatment are 
encouraging because most patients belonging to both 
categories were still being treated after >4 years and 
had normal renal function and unremarkable renal 
histologic findings. 
CONCLUSIONS 
In this study of patients with SRNS and FSGS, low-dose 
CsA reduced proteinuria in some patients with SRNS. 
This beneficial effect was associated with maintenance 
of normal renal function over time. Renal fibrosis was 
rare in patients treated with CsA for >4 years, suggest- 
ing a good safety profile of the drug with these patients. 
These data suggest that low-dose CsA may have a role 
in the long-term management of SRNS. 
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